BioSpace News Archive

Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com/ ). Enzolytics continues to make significant progress in its multiple therapeutic platforms and outlines here the technical aspects of the implementation of those programs and the Company’s plans for the future.

OpGen, Inc. announced that its subsidiary, Curetis GmbH, and the European Investment Bank expect to restructure the repayment of the first tranche which matured on April 22, 2022.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the presentation of interim data from the ongoing RESTORE open-label extension/switch study of FT218 at the 2022 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 24-26, 2022.

Athenex, Inc., (NASDAQ: ATNX), today announced data from the ANCHOR Phase 1 study of KUR-502 during an oral presentation by Carlos Ramos, M.D., professor, Center for Cell and Gene Therapy, Baylor College of Medicine, at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT), and the Center for International Blood & Marrow Transplant Research (CIBMTR).

Vor Bio today announced that two abstracts have been accepted for poster presentations at the Keystone Symposia Precision Genome Engineering meeting, held April 27 to May 1 in Keystone, Colorado.

Mustang Bio, Inc. today announced updated interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”).

Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture.

Aeterna Zentaris Inc. today announced that results from pre-clinical studies of Aeterna’s AIM Biologicals for the potential treatment of Parkinson’s Disease (“PD”) were accepted for presentation at IMMUNOLOGY2022.

Astellas Pharma US, Inc. announced that it is accepting applications for the sixth annual Astellas Oncology C3 Prize, a global challenge that funds and advances the best non-treatment ideas to improve cancer care for patients, caregivers and the broader oncology community.

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that 400 patients have now been enrolled in the main trial population in the pivotal Phase 3 REVIVAL study.